Videos

The associate vice president of neuroscience, US Medical Affairs at Eli Lilly discussed the Think Talk Treat Migraine program which encourages both medical professionals and patients to identify migraine's effects. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending August 12, 2023. [WATCH TIME: 3 minutes]

The associate vice president of neuroscience, US Medical Affairs at Eli Lilly talked about the impact of migraine on women and the importance of primary care in managing this widespread condition. [WATCH TIME: 4 minutes]

The professor of anesthesiology at Washington University in St. Louis provided perspective on the respect and approach that comes with conducting research in underserved or impoverished communities. [WATCH TIME: 4 minutes]

The director of movement disorders at the Banner Sun Health Research Institute talked about alternative approaches for treating essential tremor beyond medications, and developments in the diagnostic criteria for Lewy body disorders. [WATCH TIME: 5 minutes]

The associate professor of neurology at the Indiana University School of Medicine discussed the screening paradigm for Alzheimer disease, and the reluctancy to use new digital tools over traditional methods. [WATCH TIME: 6 minutes]

The professor of neurology and residency program director at MedStar Georgetown University Hospital spoke to the evolution of the utility of botulinumtoxins in the treatment of patients with Parkinson and other movement disorders. [WATCH TIME: 4 minutes]

Bruce Cree, MD, PhD, MAS, presents his final thoughts for clinicians on the safety, efficacy, and tolerability of sphinogine-1-phospate (S1P) receptor modulators in the treatment of multiple sclerosis (MS).

Bruce Cree, MD, PhD, MAS, discusses new data presented at the 2023 European Academy of Neurology (EAN) congress on BTK inhibitors, such as Tolebrutinib, evobrutinib, renibrutinib, and fenibrutinib. Dr Cree also highlights important safety information and adverse events identified in these studies.

Bruce Cree, MD, PhD, MAS, provides his clinical advice on managing treatment cessation of sphinogine-1-phospate (S1P) receptor modulators while preventing multiple sclerosis (MS) disease rebound.

Bruce Cree, MD, PhD, MAS, discusses how sphinogine-1-phospate (S1P) receptor modulators may suppress a patients immune system and key considerations clinicians should make in light of this.

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, discussed patient reluctance towards new treatments for Parkinson disease and the role of education in defining treatment expectations for patients. [WATCH TIME: 4 minutes]

Bruce Cree, MD, PhD, MAS, discusses the data of long-term studies on fingolimod and ponesimod in relapsing-remitting multiple sclerosis (RRMS) and siponimod in secondary-progressive multiple sclerosis (SPMS).

Bruce Cree, MD, PhD, MAS, reviews the results of the long-term efficacy and safety study of ozanimod, DAYBREAK, in relapsing-remitting multiple sclerosis (RRMS) published last year. Dr Cree also discusses two other safety studies presented at the 2023 European Academy of Neurology (EAN) congress.

Bruce Cree, MD, PhD, MAS, discusses key considerations when selecting one of the four FDA approved sphinogine-1-phospate (S1P) receptor modulators for multiple sclerosis (MS). Dr Cree also highlights a particular adverse event observed in the extension studies of these four S1P receptor modulators.

Bruce Cree, MD, PhD, MAS, discusses the pathophysiology of multiple sclerosis (MS) and how sphinogine-1-phospate (S1P) receptor modulators address the underlying causes. Dr Cree also discusses the differences between the four FDA approved drugs for MS: fingolimod, siponimod, ozanimod, and ponesimod.

The pediatric neurologist at Johns Hopkins Medicine provided commentary on the steps needed to improve treatment optimization in SMA, and the unanswered questions regarding the key biology of the disease.

The pediatric neurologist at Johns Hopkins Medicine provided commentary on the subgroup findings from the phase 4 NURTURE study of nusinersen (Spinraza; Biogen) in presymptomatic spinal muscular atrophy. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending August 5, 2023. [WATCH TIME: 4 minutes]

The director at the Foundation for the National Institutes of Health discussed relevant biomarkers for Alzheimer disease and their role as novel therapeutics continue to emerge. [WATCH TIME: 5 minutes]

The director of movement disorders at the Banner Sun Health Research Institute discussed the challenges in diagnosing atypical Parkinsonian disorders and the potential role of biomarkers in improving diagnostic accuracy. [WATCH TIME: 5 minutes]

The pediatric neurologist at Johns Hopkins Medicine discussed the importance of early diagnosis in SMA, and the notable barriers that come with obtaining disease-modifying therapies. [WATCH TIME: 4 minutes]

The director of the Movement Disorders Center at Baylor University Medical Center in Dallas, a part of Baylor Scott & White Health, discussed the current state of treatment for Parkinson disease and gene therapy as a promising treatment for the management of the disease. [WATCH TIME: 5 minutes]

The director of research for internal medicine and geriatrics at Indiana University School of Medicine discussed the advantages digital assessments bring to clinics, and what role they will play in the coming years. [WATCH TIME: 3 minutes]

The associate professor in the department of population and quantitative health sciences at Case Western Reserve University School of Medicine talked about the presentation of multiple sclerosis in Latinx individuals compared with White Americans. [WATCH TIME: 5 minutes]

The PhD student in the department of electrical and computer engineering at Johns Hopkins University discussed the use of artificial intelligence and image harmonization techniques to address the challenges caused by multisite effects in neuroimaging. [WATCH TIME: 4 minutes]

Episode 36 of the AUPN Leadership Minute features Rohit Das, MD, of University of Texas Southwestern Medical Center at Dallas; and David G. Standaert, MD, PhD, of the University of Alabama at Birmingham. [WATCH TIME: 4 minutes]

The assistant professor of neurology at the University of Colorado School of Medicine talked about the importance of addressing family planning with patients with multiple sclerosis. [WATCH TIME: 5 minutes]

The neurologist at NorthShore University Health System in Chicago discussed a retrospective study on patients with multiple sclerosis who switched from high or moderate efficacy disease-modifying therapies to lower efficacy ones. [WATCH TIME: 5 minutes]

The associate professor of neurology at the University of Colorado School of Medicine discussed results of phase 3 studies assessing therapeutics on the impact of fatigue experienced by patients with multiple sclerosis. [WATCH TIME: 5 minutes]